RIBOCYTOKINE

Serial Number 79266179
Registration 6093112
700

Registration Progress

Application Filed
Apr 30, 2019
Under Examination
Approved for Publication
Apr 21, 2020
Published for Opposition
Apr 21, 2020
Registered
Jul 7, 2020

Attorney Assistance

Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20200707)
Due: Jul 07, 2026 186 days

Trademark Image

RIBOCYTOKINE

Basic Information

Serial Number
79266179
Registration Number
6093112
Filing Date
April 30, 2019
Registration Date
July 7, 2020
Published for Opposition
April 21, 2020
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jul 7, 2020
Registration
Registered
Classes
001 005 040 042
+1 more

Rights Holder

BioNTech SE

27
Address
An der Goldgrube 12
55131 Mainz
DE

Ownership History

BioNTech RNA Pharmaceuticals GmbH

Original Applicant
27
DE

BioNTech RNA Pharmaceuticals GmbH

Owner at Publication
27
DE

BioNTech SE

Original Registrant
27
DE

Legal Representation

Attorney
Monica Riva Talley

USPTO Deadlines

Next Deadline
186 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20200707)
Due Date
July 07, 2026
Grace Period Ends
January 07, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

31 events
Date Code Type Description Documents
Jul 7, 2025 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Loading...
Jan 31, 2025 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
May 30, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
May 30, 2024 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Loading...
May 30, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
May 30, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 30, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
May 30, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Nov 19, 2021 ADCH M CHANGE OF NAME/ADDRESS REC'D FROM IB Loading...
Jan 10, 2021 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Oct 30, 2020 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Oct 29, 2020 FIMP P FINAL DISPOSITION PROCESSED Loading...
Oct 7, 2020 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Jul 7, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 21, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 21, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 1, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 19, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 18, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 18, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 18, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 16, 2020 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Oct 12, 2019 RFNT P REFUSAL PROCESSED BY IB Loading...
Sep 20, 2019 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Sep 20, 2019 RFRR P REFUSAL PROCESSED BY MPU Loading...
Sep 13, 2019 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Sep 10, 2019 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Sep 9, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 9, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 9, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 29, 2019 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 001
Chemical agents for laboratory use, in particular nucleic acids, peptides and proteins; chemical agents for the production of anticancer drugs and vaccines, in particular nucleic acids, peptides and proteins
Class 005
Pharmaceutical products for treating cancerous diseases, infections and autoimmune disorders
Class 040
Treatment and conversion of material, namely, custom manufacturing of chemical and biochemical preparations; custom manufacturing of biopharmaceuticals, chemical agents for laboratory use, in particular nucleic acids, peptides and proteins, pharmaceutical products of all kinds, in particular for treating cancerous diseases, infections and autoimmune disorders, and of chemical agents for the production of anticancer drugs and vaccines, in particular nucleic acids, peptides and proteins; custom manufacturing of therapeutic pharmaceuticals
Class 042
Scientific research for medical purposes, in particular for developing treatment concepts for cancerous diseases, infections and autoimmune diseases
Class 044
Medical and veterinary services in connection with the treatment of cancerous diseases, infections and autoimmune disorders

Classification

International Classes
001 005 040 042 044